Josh Nathan-Kazis

The Trump administration's Monday executive order could restructure how Americans buy prescription drugs, pushing them away from insurers and pharmacy-benefit managers and toward cash pay options.

Less than a month after a dramatic cut to UnitedHealth Group’s guidance set off a historic selloff in the insurance giant’s shares, the company has pulled its entire 2025 outlook and announced that its CEO had stepped down. The company said its CEO, Andrew Witty, was stepping down for “personal reasons.” Steep selloffs have greeted UnitedHealth’s past three quarterly reports, culminating in the April guidance cut that led to a 27% two-day tumble in UnitedHealth’s stock price.

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may translate into big problems for Johnson & Johnson, Merck, and other drugmakers.

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may translate into big problems for Johnson & Johnson, Merck, and other drugmakers.

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

UNH has lost more than $200 billion in market value in the last six months. The company’s old CEO sees a fix. Investors should be wary.

Danish drugmaker Novo Nordisk, which makes the weight loss drug Wegovy, has only had five CEOs over the past century.

Biotech Regeneron already faces enough of its own challenges without taking on a the troubled legacy of genetic-testing firm 23andMe.

The Food and Drug Administration will only stick to its existing process for updating Covid-19 shots for older adults and those at a high risk of severe illness, the agency’s head wrote in a medical journal article on Tuesday. In order to get new Covid-19 shots approved for younger, healthy adults, drugmakers will need to run new randomized clinical trials, FDA commissioner Dr. Marty Makary wrote. The question weighing on Moderna and other Covid-19 vaccine stocks in recent weeks has been whether the FDA will require drugmakers to run a new randomized, controlled trial before approving any updates to their Covid-19 vaccines.

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 billion, as well as royalties if the treatment is approved.